Back to top

gene-editing: Archive

Zacks Equity Research

RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag

Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.

ALNYPositive Net Change CPRXNegative Net Change ANIPPositive Net Change RAREPositive Net Change